JOSHUA CLEMMER: Open Payments
NPI 1730775784 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$349 in 18 payments from 8 companies in 2025. Trend: 2023 $669 · 2024 $733 · 2025 $349
Food & beverage: $349
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 4 | $77 |
| ABBVIE INC. | 4 | $65 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| Neurocrine BioSciences, Inc. | 2 | $41 |
| Sage Therapeutics, LLC | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
Products named: COBENFY, VRAYLAR, INVEGA SUSTENNA, INGREZZA, ZURZUVAE, CAPLYTA, REXULTI, ABILIFY MAINTENA.
Industry payments across NV — which companies pay providers there.
